Healthcare GSK Beats on Profit but Investors Punish a Slide in Vaccine SalesBy Naomi ChanOctober 31, 2026 GSK beat expectations on revenue and profit in the third quarter, yet its shares fell as much as 7% because vaccine sales went backwards. It is a sharp lesson in how markets judge a company by its weakest engine, not its average.
